MGA : Réduction graduelle de la dose de mycophénolate mofétil après des années sans évolution de la maladie semble sûre

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 8.1 Firefox

MGA : Réduction graduelle de la dose de mycophénolate mofétil après des années sans évolution de la maladie semble sûre

Message par Pboulanger Prés. »

:hi:

Lu sur Willey on line http://onlinelibrary.wiley.com/doi/10.1 ... 4/abstract
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Image

Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis
Lisa D. Hobson-Webb MD1,*, Michael Hehir MD2, Brian Crum MD3, Amy Visser MD3, Donald Sanders MD1 andTed M. Burns MD4
Abstract :
  • Introduction:
    Mycophenolate mofetil (MMF) is frequently used to treat myasthenia gravis, but there is little information to guide clinicians on the safety of reducing the dose in well-controlled patients.

  • Methods:
    This retrospective chart review at 3 institutions identified 92 patients who had undergone MMF taper after achieving either pharmacologic remission or minimal manifestations status. Statistical analysis was performed to assess differences in patient characteristics between patients who had successfully tapered MMF and those who relapsed.

  • Results:
    Of 92 patients undergoing a taper, 30 relapsed. The relapses were mild, transient, and usually responded to increased MMF dose. MG crisis did not occur. The mean dose at time of relapse was 888 mg/day. Patients with relapses were tapered more quickly (8.4 vs. 62.4 months).

  • Conclusions:
    Tapering MMF appears safe after years of disease stability. Reducing the dose at a dose of only 500 mg/day every 12 months is recommended.

Muscle Nerve 52: 211–215, 2015
Amicalement,
Image
Verrouillé

Retourner vers « 2015 »